title: Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.
abstract: During the last few decades, the discovery of novel targets for therapeutic intervention led to the development of chemotherapeutic agents that specifically interfere with altered cellular functions of tumour cells. Genetic alterations in glioblastoma affect cell proliferation and cell cycle control, as well as invasive and metastatic growth. Therefore, innovative therapeutic strategies have been based on drugs targeting cellular proliferation, invasion, angiogenesis, metastasis and differentiation of tumour cells. Furthermore, disruption of cell-death pathways also contributes to the pathogenesis of glioblastoma and may result in resistance to chemotherapy and radiation. Therefore, additional treatment strategies that target intracellular survival and/or apoptotic pathways are under current laboratory investigation. The progress in the understanding of glioblastoma tumour biology and the refined diagnosis of individual patients together with the exploration of targeted drugs may allow a risk-adapted, individualised therapeutic strategy and will hopefully improve prognosis of glioblastoma patients in the future.
authors.affiliation: Department of Radiation Oncology, Hoppe-Seyler-Strasse 3, D-72076 Tübingen, Germany. verena.jendrossek@uni-tuebingen.de
authors.forename: Verena
authors.initials: V
authors.lastname: Jendrossek
authors.forename: Claus
authors.initials: C
authors.lastname: Belka
authors.forename: Michael
authors.initials: M
authors.lastname: Bamberg
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001932:Brain Neoplasms / Q000188:drug therapy*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D000077146:Irinotecan; D061965:Matrix Metalloproteinase Inhibitors; D015398:Signal Transduction / Q000187:drug effects; D000077204:Temozolomide
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D000077146:Irinotecan; D003606:Dacarbazine; D066246:ErbB Receptors; D002166:Camptothecin; D000077204:Temozolomide